Results 231 to 240 of about 23,450 (303)

Does IL-31 level have more significance in chronic urticaria, when compared with IL-33 level? [PDF]

Postepy Dermatol Alergol
Özden G, Acık DY, Tekin A, Bankir M, Cevirme L, Solak Y.   +5 more
europepmc   +1 more source

Substitution Patterns After Discontinuation of CNS‐Active Medications in Older Adults in Primary Care

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Little is known about substitution of alternative medications in the context of deprescribing. The objectives were to: (1) determine the frequency of medication substitutions among those who discontinued a central nervous system (CNS)‐active medication, and (2) characterize substitutions as potentially inappropriate (as per the 2023
Shelly L. Gray, Annalisa V. Piccorelli, Laura A. Hart, Andrea J. Cook, Brian D. Williamson, Benjamin H. Balderson, Elizabeth A. Phelan   +6 more
wiley   +1 more source

Standardized pressure provocation as an objective clinical marker of omalizumab response in delayed pressure urticaria: an open-label, real-life, prospective cohort. [PDF]

Front Immunol
Konstantinou GN, Podder I.
europepmc   +1 more source

Anticholinergic Medication Use in Veterans Affairs Long‐Term Care Residents: Clinical Patterns and Opportunities for Deprescribing

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Anticholinergic exposure is common in nursing homes; however, the true burden may be underestimated, particularly due to over‐the‐counter agents such as first‐generation antihistamines that are not consistently captured in prior claims‐based studies.
Cellas A. Hayes, Yongmei Li, Bocheng Jing, Laura A. Graham, Chintan Dave, Michelle C. Odden   +5 more
wiley   +1 more source

Successful treatment of chronic spontaneous urticaria and bladder pain syndrome with montelukast and/or omalizumab: a case report. [PDF]

J Med Case Rep
Bulut G.
europepmc   +1 more source

Expired fexofenadine hydrochloride acts as a high-performance sustainable corrosion inhibitor for copper in MSF desalination applications. [PDF]

Sci Rep
Khafagy ES, Ashmawy AM, Abu Lila AS, Al Saqr A, Aldawsari MF, Deyab MA.   +5 more
europepmc   +1 more source

Effectiveness of the antihistamine and anti-PAF effects of rupatadine in allergic diseases: off-label use in a case series study. [PDF]

Drugs Context
Aguiar R, Albores-Arguijo RC, Cichocka-Jarosz E, Jerzynska J, Mack DP.   +4 more
europepmc   +1 more source

Angioedema in Primary Care: Disease Course and Its Relation to ACE Inhibitor Use

International Journal of Dermatology, EarlyView.
Reineke Soegiharto, Sandra Aborah, Nicole Boekema‐Bakker, Irene A. M. Groenewegen, André C. Knulst, Juul M. P. A. van den Reek, Heike Röckmann   +6 more
wiley   +1 more source

Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increased risk of infusion-related reactions. [PDF]

Mult Scler J Exp Transl Clin
Schoof LG, Hogenboom L, van Kempen ZL, Killestein J, van Oosten BW, Strijbis EM.   +5 more
europepmc   +1 more source

Serum Neuropeptides in Chronic Spontaneous Urticaria: Associations With Disease Activity and Clinical Phenotypes. [PDF]

Allergy Asthma Immunol Res
Shi Z, Deng X, Ren J, Lu S, Tan G.
europepmc   +1 more source